FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Keeps Buy Rating On Shares Of Bristol-myers Squibb Company

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $73 from $69, 11.7x our 2027 EPS estimate, a discount to BMY's 10-year historical forward P/E average. We lift our 2026 EPS estimate to $6.30 from $6.22 and maintain our 2027 EPS forecast at $6.18. BMY announced Q1 revenues of $11.5B, a 1% Y/Y increase, and non-GAAP EPS of $1.58, above expectations. The company's growth portfolio, which includes key products such as Reblozyl, Breyanzi, Opdualag, Qvantig, and Cobenfy, and is a key area of focus, saw a 9% Y/Y increase in sales, driven by strong demand for BMY's newer medicines. The quarter was also marked by significant progress in the company's pipeline, with positive data for its CELMoD program and advancements in several late-stage assets. We think the company is successfully navigating a period of important transition, with strong performance from its growth portfolio offsetting declines in legacy products, as we anticipate a series of crucial clinical trial readouts later in the year.

Related Articles

Research

Research Alert: CFRA Maintains Strong Sell Opinion On Shares Of Sna

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target to $325 from $330, as we revise our outlook lower following Q1 earnings. Our updated target values shares at 15.5x our 2027 EPS outlook of $21.12 (down from $21.28; 2026 EPS updated to $19.63 from $19.91), in line with SNA's long-term historical multiple average but below industrial machinery peers. Our Strong Sell view is unchanged following SNA's Q1 print. Margin contraction seen in the first quarter is not an existential threat for SNA, though we believe that earnings growth will be largely limited without underlying profitability inflecting higher. Tariffs and rising material costs ate into SNA's bottom-line during Q1, though organic sales growth was more of a positive. Demand headwinds with OEM dealerships contributed to our revision in EPS growth assumptions for 2026 and 2027, with Repair Systems now set to be less of a contributor to organic sales expansion, in our view.

$SNA
US Markets

Cava Could Beat Quarterly Same-Store Sales Views, Lift 2026 Outlook Amid Continued Momentum, RBC Says

Cava Group's (CAVA) first-quarter same-store sales are expected to top Wall Street's estimates amid continued momentum, which could prompt the company to raise its full-year outlook, RBC Capital Markets said in a note e-mailed Friday.The brokerage projects the fast-casual restaurant chain's same-store sales for the quarter to rise 6%, while the Street is looking for 5.9% growth, according to the RBC note to clients. Cava is scheduled to report results May 19."Thus far this earnings season, restaurant winners (and) losers have largely been defined by sensitivity to (the Middle East) conflict-related macro headwinds," RBC analyst Logan Reich said. "For Cava, we don't think their traffic is materially impacted, where their relatively high-income consumer exposure should insulate them from higher gas prices."Energy prices have jumped as the US-Israel war with Iran has curtailed shipments through the crucial Strait of Hormuz. The war, which started at the end of February, paused following a recent ceasefire between Washington and Tehran, though a framework for a permanent truce is yet to be reached.US retail gasoline prices averaged $4.392 per gallon Friday, compared with $3.187 a year ago, according to data from AAA, a travel organization that tracks fuel prices in the country.Cava started the year with comparable sales momentum, which could continue through 2026 amid "menu innovation, digital improvements, and easing compares," Reich said. These factors could help drive upward revisions to the company's own full-year outlook for same-store sales to grow between 3% and 5%, which the brokerage said was "conservative."RBC raised its price target on Cava's stock to $100 from $90 with an outperform rating.The company's shares were down 2.5% in Friday late-afternoon trade. So far in 2026, the stock has surged 56%.Despite the shares' significant year-to-date outperformance, RBC said it's leaning "constructive" into Cava's upcoming results."We theorize there's potential consumer reversion towards the fast-casual category this year, as consumers could increasingly prioritize healthier (and) wellness, which Cava should benefit from, following a material slowdown across the category in (2025) as quick-service chains took share driven by incremental value offerings," Reich said.Price: $91.09, Change: $-2.33, Percent Change: -2.49%

$CAVA
Sectors

Sector Update: Consumer Stocks Mixed Late Afternoon

Consumer stocks were mixed late Friday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) decreasing 0.2% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) rising 0.6%.In sector news, Spirit Airlines failed to secure sufficient support from certain bondholders and the federal government for a $500 million lifeline, The Wall Street Journal reported. As a result, the airline is preparing to cease operations, the report said.In corporate news, Colgate-Palmolive (CL) shares rose 1.8% after the company reported Q1 results that topped analysts' expectations.The United Auto Workers union intends to hold a vote next week over whether to strike at a Stellantis (STLA) pickup truck factory in Suburban Detroit, Bloomberg reported, citing a UAW podcast. Stellantis shares were down 1.6%.Newell Brands (NWL) raised its 2026 sales outlook, crediting tax refunds, operational improvements, and better-than-expected consumer demand. Its shares jumped past 9%.Estee Lauder (EL) lifted its full-year earnings outlook on Friday as the cosmetics company said it aimed to lay off more staff than previously planned as part of an ongoing restructuring program. Its shares rose 2.4%.

$CL$EL$NWL$STLA